From the test tube to the treatment room: Fundamentals of boron-containing compounds and their relevance to dermatology

Journal of Clinical and Aesthetic Dermatology

Volumn 7, Issue 2, 2014, Pages 13-21

  Del Rosso, James Q ^a,b   Plattner, Jacob J ^c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b Las Vegas Skin & Cancer Clinics Ltd   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894482680     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Eaglstein WH, Cash KR, Corcoran GR. Challenges encountered in dermatologic drug development. Actas Dermosifiliogr. 2009;100(Suppl 1):86-91.
2. Ehrenberger HE, Joshi T. Dermatology clinical trials and drug development. Dermatol Nursing. 2003;15(5). www.medscape.com/viewarticle/464022
3. Svensson L, Røpke MA, Norsgaard H. Psoriasis drug discovery: methods for evaluation of potential drug candidates. Expert Opin Drug Discov. 2012;7:49-61.
4. Eaglstein WH. The FDA drug approval process. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 41-45.
5. Leyden JJ, Del Rosso JQ, Baum E, et al. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. J Clin Aesthet Dermatol. 2014 (accepted for publication).
6. Magel GD, Haitz KA, Lapolla WJ, et al. Systemic antiviral agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 121-128.
7. Patton TJ, Ferris LK. Systemic retinoids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 252-258.
8. Bhutani T, Lee CS, Koo JYM. Cyclosporine. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 199-202.
9. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http://www.fda.gov/Drugs/DrugSafety/ ucm362415.htm. Accessed on July 26, 2013.
10. Gupta AK. Systemic antifungal agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 98-120.
11. Kim S, Michaels BD, Kim GKK. Systemic antibacterial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 3rd ed. Philadelphia: Elsevier-Saunders; 2013: 61-95.
12. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25(2):127-132. (Pubitemid 46566394)
13. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10(7):724-733.
14. Leyden JJ, Del Rosso JQ, Webster, GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Dermatol Clin. 2009;27(1):1-15.
15. Del Rosso JQ. Cephalosporins in dermatology. Clin Dermatol. 2003;21(1):24-32. (Pubitemid 36287028)
16. Baker SJ, Ding CZ, Akama T, et al. Therapeutic potential of boron-containing compounds. Future Med Chem. 2009;1(7):1275-1288.
17. Ciaravino V, Plattner J, Chanda A. An assessment of genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013;54:338-346.
18. Akama T, Baker SJ, Zhang Y-K, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Medic Chem Letters. 2009;19:2129-2132.
19. Baker SJ, Zhang Y-K, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) for the potential treatment of onychomycosis. J Medic Chem. 2006;49(15):4447-4450. (Pubitemid 44162669)
20. Akama T, Dong, D, Virtucio C, et al. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency Rho kinase inhibitors. J Pharmacol Exp Ther. 2013;347:615-625.
21. Groziak MP. Boron therapeutics on the horizon. Am J Ther. 2001;8:321-328. (Pubitemid 33753128)
22. Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003;23(3):346-368. (Pubitemid 36457539)
23. Morandi S, Morandi F, Caselli E, et al. Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors. Bioorg Med Chem. 2008;16:1195-1205. (Pubitemid 351191778)
24. Connolly BA, Sanford DG, Chiluwal AK, et al. Dipeptidyl boronic acid inhibitors of dipeptidyl peptidase IV: determination of potency and in vivo efficacy and safety. J Med Chem. 2008;51:6005-6013.
25. Gronowitz S, Dahlgren T, Namtvedt J, et al. Antibacterial borazaro derivatives II: effect of substituents on the antibacterial activity of 5-arylsulfonyl-4-hydroxy-4,5-borazothieno[2,3-c]pyridines and 6-arylsulfonyl-7-hydroxy-7,6-borazothieno[3,2-c]pyridines. Acta Pharmaceutica Suecica. 1971;8(6):623-638.
26. Byrn SR, Tishmack PA, Milton MJ, et al. Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile. AAPS Pharm Sci Tech. 2011;12(2):461-467.
27. Alley MRK, Baker S, Beutner K, et al. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16(2):157-167. (Pubitemid 46206630)
28. Jacobs RT, Nare B, Wang s, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African Trypanosomiasis. PLOS Neglected Tropical Diseases. 2011;5(6):e1151. Published online 2011 June 28.
29. Baker SJ, Hui X, Sanders V, et al. Nail penetration of AN2690: efficacy coefficient and effect on formulation. Poster presented at: European Society for Dermatologic Research, 36th Annual Meeting; Paris, France; September 7-9, 2006.
30. Beutner K, Sanders V, Bullington R, et al. An open-label, multiple-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate-to-severe onychomycosis. Poster presented at American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2-6, 2007.
31. Baker SJ, Sanders V, Plattner J, et al. Human nail penetration of AN2690, a new antifungal agent in development for the topical treatment of onychomycosis. Poster presented at: Perspectives in Percutaneous Penetration (PPP), 10th International Conference; Grande Motte, France; April 16, 2006.
32. Hold KM, Bu W, Sanders V, et al. In vivo nail residence of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Poster presented at: American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2-6, 2007.
33. Zane LT, Pollak RA. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule in Phase 2 trials for topical treatment of toenail onychomycosis. Poster presented at: National American Podiatric Medical Association Annual Scientific Meeting; Washington, D.C.; August 16-19, 2012.
34. Anacor Pharmaceuticals to present pivotal phase 3 data of tavaborole for the topical treatment of toenail onychomycosis. Acquire Medie; press release; July 18, 2013.
35. Akama T, Sanders V, Graves G, et al. Discovery of novel boron containing compounds as dual inhibitors of TNFα anf IL-23 release. Poster presented at: World Congress of Inflammation; Tokyo, Japan; July 6-10, 2009.
36. Wigger-Alberti W, Zane LT. Dermal tolerability and preliminary efficacy of AN2728 and A2898, novel boron-based small molecules, in the treatment of psoriasis. Poster presented at: Annual Meeting of the European Society for Dermatologic Research; Barcelona, Spain; September 7-10, 2011.
37. Zane LT, Tom WL, Chanda S, et al. Safety, pharmacokinetics and efficacy of AN2728 ointment, 2% in a phase 2 study of adolescents with mild-to-moderate atopic dermatitis. Poster presented at: IID 2013; Edinburgh, Scotland; May 8-11, 2013.
38. Ip EY, Baker SJ, Hold KM, et al. Skin penetration and anti-inflammatory activity of AN2728, a novel oxaborole. Poster presented at: American Academy of Dermatology, 65th Annual Meeting; Washington, D.C.; February 2-6, 2007.